[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579062":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":25,"responsibleParty":41,"collaborators":10,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":10,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":10,"maxAge":10,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":10,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Sichuan Provincial People's Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Treatment with polyene antifungal drugs",null,"The dosage and course of Amphotericin B or Amphotericin B cholesteryl sulphate complex were determined by clinicians, and this study was registered according to clinical practice",{"label":13,"type":10,"description":14,"interventionNames":10},"Treatment with azole antifungal drugs","The dosage and course of triazoles or imidazole antifungal drugs were determined by clinicians, and this study was registered according to clinical practice",[16],{"name":17,"affiliation":5,"role":18},"lingai PP Pan, PhD","STUDY_CHAIR",[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"lingai Pan, PhD","CONTACT","17708130236","panlingai2004@163.com",[26],{"facility":5,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Chengdu","Sichuan","610072","China","CN",{"type":34,"coordinates":35},"Point",[36,37],104.06667,30.66667,{"lat":37,"lon":36},[40],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Lingai Pan","Deputy Chief Physician","100579062","efficacy-and-safety-of-amphotericin-b-and-azoles-in-the-treatment-of-invasive-fungal-disease-100579062",false,"NCT06819410","Efficacy and Safety of Amphotericin B and Azoles in the Treatment of Invasive Fungal Disease","A Retrospective Clinical Study on the Efficacy and Safety of Amphotericin B Compared With Azoles in the Treatment of Invasive Fungal Disease","Inclusion Criteria:\n\n* There is no age limit, gender is not limited\n* Patients with invasive fungal disease who are treated with polyene antifungals or azole antifungals should be treated for ≥ 7 days.\n\nExclusion Criteria:\n\n* Patients with incomplete data or other factors affecting the clinical outcome judgement\n* Patients who are judged by the investigator to be unsuitable to participate in this study.","ALL",{"count":54,"type":55},1000,"ESTIMATED","OBSERVATIONAL","Efficacy and safety of amphotericin B and azoles in the treatment of invasive fungal disease",[59],"Invasive Fungal Disease","2025-02-10",{"date":62,"type":63},"2025-02-11","ACTUAL",{"date":65,"type":63},"2021-05-01",{"date":67,"type":55},"2025-02-01",{"name":5,"class":6},1]